Accu check glucose monitor

All animal experiments in this study were approved by the Institutional Animal Care and Use Committee of the Third Xiangya Hospital, Central South University, Hunan, China. Thirty 8-week-old male Sprague–Dawley rats were used for this study. Of these, 24 DM rats were induced by intraperitoneally with STZ (60 mg/kg), and the others injected with citrate phosphate buffer, used as the control group (Control, n = 6). At 72 hours after STZ injection, DM was confirmed by blood glucose levels, which were measured with Accu-Check glucose monitor (Roche Diagnostics, Mannheim, Germany) and only rats with fasting glucose levels higher than 16.7 mmol/L were selected as DM.²⁰ (link)
8 weeks later, all rats with DM had survived. An APO test was used to assess the DMED status. Of all the DM rats, 14 with APO-negative results were used in subsequent experiments. The rats were randomly divided into 2 groups. One group with DMED was treated with gavage administration TM 10mg/kg¹⁶ (link)^,21 (link) (dissolved in doubly distilled water) every day for 4 weeks (DMED+TM, n = 7), and the other group was treated with phosphate buffer solution (PBS) on the same schedule (DMED+PBS, n = 7).

Healthy male C57BL/6 WT 6 weeks old mice were given IP injection every other day (3 times a week) with vehicle containing or not MK-28 (6 ​mg/kg). Blood glucose level measurements (on mice with free access to food and water) were taken from a small cut at the tip of the tail and measured with an Accu-Check glucose monitor (Roche Diagnostics, USA). Weight was monitored weekly for 6 weeks in total. At the age of 12 weeks, the mice were sacrificed by CO₂, and blood samples were collected and sent to an external company (ALM) for analyzing liver function markers. Brains were taken for future analysis and kept at −80 ​°C.